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Abstract
Introduction. Liquid biopsies are noninvasive tests using blood or body fluids to detect circulating tumor cells 
(CTCs) or the products of tumor cells, such as fragments of nucleic acids or proteins that are shed into biolo-
gical fluids from primary tumor or its metastates. The analysis of published clinical studies provides coherent 
evidence that the presence of CTCs detected in peripheral blood is a strong prognostic factor in patients with 
colorectal carcinoma (CRC). The aim of the study was to implement size-based separation protocol of CTCs 
in CRC patients. 
Material and methods. Patients diagnosed with different stages of CRC (n = 98) were included in the study. 
All patients have been diagnosed for colorectal adenocarcinoma by pathology examination, 45 patients with 
colon carcinoma and 53 with rectosigmoid cancer. A size-based separation method (MetaCell®) for viable CTC 
enrichment from peripheral blood was used to assess the presence of CTCs by cytomorphological evaluation 
using vital fluorescence microscopy.
Results. Cytomorphological analysis revealed that 81 (83%) tested samples were CTC-positive and 17 (17%) 
were CTC-negative. We report a successful isolation of CTCs with proliferation potential in patients with CRC. 
The CTCs were cultured in vitro for further downstream applications. Some of the isolated CTCs were able to 
grow in vitro for 6 months as a standard cell culture. 
Conclusions. We established a reliable, inexpensive and relatively fast protocol for CTCs enrichment in CRC 
patients by means of vital fluorescence staining which enables their further analysis in vitro. 
(Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 1, 1–5)
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attention in cancer diagnosis, risk stratification and 
monitoring treatment response. Liquid biopsies are 
noninvasive tests using blood or bodily fluids to detect 
circulating tumor cells (CTCs) or the products of 
tumor cells, such as fragments of nucleotides or pro-
teins that are shed into biological fluids from primary 
or metastatic tumors [1]. The analysis of published 
clinical studies provides coherent evidence that the 
presence of CTCs detected in peripheral blood is 
a strong prognostic factor in patients with colorectal 
carcinoma (CRC) [1–3]. 
Introduction 
An idea of a minimally invasive way to obtain accu-
rate information on tumors from a blood sample, 
also known as liquid biopsy, has gained increasing 
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The majority of the studies used immunomagnetic 
methods or RT-PCR for CTCs detection [1, 3–5]. 
These methods are dependent on specification of 
separated CTCs, especially, their cell surface antigens 
such as epithelial cell adhesion molecule (EPCAM) 
or they rely on a specific targeting of RNA sequenc-
es. This seems problematic for these methods because 
one of the key aspects that emerged from the analysis 
of CTCs is their remarkable heterogeneity, both con-
sidering the expression of specific cancer-associated 
markers, and also their phenotypic characteristics 
such as tumor-seeding potential. Therefore, we have 
taken a different approach based on the implementa-
tion of cell-size separation protocol of CTCs in CRC 
patients. This study presents first data of the appli-
cation of this method to determine the occurrence of 
CTCs in the differently staged CRC patients.
Material and methods
Patients. To date 98 patients with diagnosed CRC have been 
enrolled into the study in accordance with the Declaration of 
Helsinki. All patients were candidates for surgery or surgical 
diagnosis. Based on the informed consent, clinical data were 
collected from all patients. For each patient, approximately 
18 mL of venous blood was drawn from the antecubital vein 
and placed into S-Monovette tubes (Sarstedt AG & Co., 
Numbrecht, Germany) containing 1.6 mg EDTA/mL of 
blood as an anticoagulant. The samples were processed at 
room temperature using an isolation procedure completed 
within 24 hours after the blood draw.
CTCs enrichment and culture. A size-based separation 
method for viable CTC enrichment from peripheral 
blood has recently been introduced (MetaCell®, MetaCell 
s.r.o., Ostrava, Czech Republic) [6, 7]. The size-based en-
richment process is based on the filtration of peripheral 
blood through a porous polycarbonate membrane (with 
pores of 8 μm diameter). The minimum and maximum 
volume of the filtered peripheral blood may be adjusted 
up to 50 mL with physiological fluid. The standard 8 mL 
peripheral blood sample from patients suffering from 
CRC was transferred into the filtration tube. Detailed 
separation protocol has been described previously [8–10]. 
The CTCs were grown in RPMI medium with 10% fetal 
blood serum (FBS, both purchased from Sigma-Aldrich, 
St. Louis, MO, USA) for a minimum of 3 days on the 
membrane. Alternatively, the enriched CTCs fraction can 
be transferred from the membrane and cultured directly 
on any plastic surface or a microscopic slide, or the sep-
aration membrane may be transferred on a microscopic 
slide. Microscopic slide is preferred if cytological analysis 
is planned. If an intermediate analysis of CTCs is awaited, 
the CTCs fraction is transferred in phosphate-buffered 
saline (PBS, 1.5 mL) to a cytospin slide. The slide is then 
dried for 24 h and analyzed by cytology (May-Grünwald 
staining) and/or by automated immunocytology protocols 
(Ventana, Benchmark Ultra, Roche, Tucson, AZ, USA) 
using standard differential diagnostic antibodies for the 
pathology evaluation process. 
Cytomorphological analysis. After 3–5 days of culture, 
nucleus and cytoplasm of viable cells were stained by vital 
fluorescent dyes Nucblue® Reagent (Thermo Fisher Scien-
tific, Waltham, MA, USA) and Celltracker™ Green CMF-
DA Dye (Thermo Fisher Scientific), respectively. Staining 
procedures followed manufacturer protocols.
The stained fixed cells captured on the membrane were 
examined using light microscopy in two steps: (i) screening 
at ×20/×40 magnification to locate the cells; (ii) observation 
at ×40/×60 magnification for detailed cytomorphological 
analysis. Isolated cells and/or clusters of cells of interest (im-
munostained or not) were selected, and their digital images 
were then examined by an experienced researcher and/or 
pathologist. CTCs were defined as cells with the following 
characteristics: (i) with a nuclear size ≥ 10 μm); (ii) irregular 
nuclear contour; (iii) visible cytoplasm, cells size over 15 μm; 
(iv) prominent nucleoli; (v) high nuclear-cytoplasmic ratio; 
(vi) presence of proliferating cell, (vii) actively invading cells 
creating 2D or 3D cell groups. 
Cell cultures of CTCs obtained from colorectal cancer 
patients. Membrane with captured cells was washed with 
RPMI medium and transferred into culture plate. Four 
mL of RPMI medium supplemented with 10% FBS, am-
photericin B (Sigma-Aldrich) and penicillin-streptomycin 
(Sigma-Aldrich) were added to the culture medium. Cap-
tured cells were cultured in vitro under standard conditions 
(37°C, 5% CO2) for 3–5 days.
Statistical analysis. The Chi-Square test  was used to de-
termine if there is a significant relationship between two 
nominal (categorical) variables (e.g. metastasis presence 
and CTC-positivity). Contingency tables in order to decide 
whether or not effects are present were analyzed (http://
vassarstats.net/newcs.html). Statistical significance of dif-
ferences between two compared groups and CTC presence 
was set at p < 0.05.
Results
Patients’ characteristics
Patients diagnosed with different stages of CRC 
(n = 98, 61 male and 37 female patients) were 
included in the study (Table 1). The median age 
was 61.7 years (range 38–90 years). All patients 
were diagnosed with colorectal adenocarcinoma by 
pathology examination, 45 patients presented with 
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Cultures of CTCs isolated from blood of colorectal 
cancer patients
We report a successful isolation of CTCs with pro-
liferation potential in patients with CRC. The cells 
captured by size-based filtration approach showed 
a viable condition, which enabled setting up cultures 
of CTCs which viability was unaffected by antibodies 
(e.g. anti-EPCAM antibodies) or lysing solutions (e.g. 
erythrocyte lysing solution). The CTCs were cultured 
in vitro for further downstream applications (Fig. 1). 
Some of the isolated CTCs were grown in vitro for as 
long as 6 months as a standard cell culture.
Discussion
The classification of tumor (pTNM staging) and the 
residual tumor status following treatment are the 
strongest predictors of outcome for patients with 
CRC. A careful pTNM classification enables an ac-
curate estimation of prognosis; therefore, it can be 
colon carcinoma and 53 with rectosigmoid cancer 
(Table 1). 
Cytomorphological analysis revealed that 
81 (83%) of all CRC patients were CTC-positive in 
peripheral blood. Into study were enrolled 45 pa-
tients with colon cancer of which 40 (89%) were 
CTC-positive and 53 patients with rectosigmoid 
cancer of which 41 (77%) patients were CTC-posi-
tive (Table 1).
The presence of CTCs in different stages of colorec-
tal cancer according to TNM classification 
The frequency of the CTC positivity is reported 
for different patient subgroups in relationship to 
tumor size, lymph node involvement and distant 
metastases. The CTC positivity for different disease 
stages and tumor grade subgroups is summarized 
in Table 1. Patients were CTC positive in majority 
of all TNM stages, and disease and grade stages 
(Table 1).
Table 1. Clinical-pathological characteristics of the colorectal cancer patients’ cohort and the occurrence of circulating 
tumor cells (CTCs) in blood
Patients n Positive CTC % Negative CTC %  p 
Colon cancer 45 40 88.89 5 11.11 n.s.
Rectosigmoid cancer 53 41 77.36 12 22.64 n.s.
Tumor size Positive CTC  Negative CTC   
T1 6 5 83.33 1 16.67 n.s.
T2 19 13 68.42 6 31.58 n.s.
T3 52 44 84.61 8 15.38 n.s.
T4 21 19 90.48 2 9.52 n.s.
Lymph node involvement Positive CTC  Negative CTC   
N0 52 43 82.69 9 17.31 n.s.
N1 20 17 85.00 3 15.00 n.s.
N2 26 21 80.77 5 19.23 n.s.
Metastasis Positive CTC  Negative CTC   
M0 67 54 80.60 13 19.40 n.s.
M1 31 27 87.10 4 12.90 n.s.
Grade Positive CTC  Negative CTC   
G1 3 3 100.00 0 0 n.s.
G2 63 50 79.37 13 20.63 n.s.
G3 32 28 87.50 4 12.50 n.s.
Stage Positive CTC Negative CTC   
I 18 14 77.78 4 22.22 n.s.
II 28 26 92.86 2 7.14 n.s.
III 18 13 72.22 5 27.78 n.s.
IV 33 28 84.85 5 15.15 n.s.
The characteristics of the patients’ cohort and CTC occurrence was compared by chi- square test. At p ≥ 0.05 the comparison showed no significant 
(n.s.) difference for the tested subgroups.
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considered the gold standard for analyzing the results 
of any treatment [11].
Similarly, CTCs enumeration has been established 
as a prognostic marker for CRC [1, 12–14]. In a large 
meta-analysis including 12 studies between 1998 and 
2011, the presence of CTCs in patients with metastatic 
colorectal cancer (mCRC) correlated with shorter 
progression-free survival (PFS) and overall survival 
(OS) [14].
Matsusaka et al. showed that patients with ≥ 3 CTCs 
in 7.5 mL blood at 2 and 8–12 weeks after initiation of 
chemotherapy had shorter median progression-free 
survival (PFS) and overall survival (OS) than patients 
with < 3 CTC counts. Patients with CTC counts ≥ 3 at 
baseline with a decrease in the CTC count to < 3 du-
ring treatment had a median PFS that was similar 
to patients with persistently low CTC counts. They 
concluded that a decrease in CTC count to < 3 at 
2 weeks after initiating chemotherapy was an indicator 
of treatment efficacy [15]. 
The use of different methodologies for CTC 
detection has shown conflicting results, and the lack 
of a standardized technology complicates the imple-
mentation of CTCs examination in routine clinical 
practice. In addition, significant differences in CTC 
detection rates among the molecular methods of their 
detection have been reported [16–18].
In comparison with other studies [1–3, 12–15] the 
detection rate of CTCs in the present study seems 
high. However, a recent study of breast cancer showed 
that tumor cells can leave the primary site very early 
during tumor progression and evolve independently 
at the metastatic site [19, 20]. The genetic analyses 
showed that 80% of metastases were derived from 
early disseminated tumor cells [20].
CTCs can be used for longitudinal molecular 
and genetic analyses of the tumor and may aid in 
targeted therapy investigations. CRC patients with 
CTCs carrying wild-type KRAS show longer PFS 
and OS when treated with chemotherapeutics and 
cetuximab [21]. The detection of KRAS mutation 
in CTCs from peripheral blood may predict the 
response to cetuximab plus chemotherapy in CRC 
patients [21]. These findings indicate that the 
detection of KRAS mutational status in CTCs by 
using gene expression array has potential clinical 
applications for selecting CRC patients who may 
benefit from cetuximab therapy.
CTCs detection and characterization may be a va-
luable tool to refine prognosis and CTCs can be pre-
dictive biomarkers in treatment of colorectal cancer. 
Here we presented high accordance of the TNM 
stages of CRC with the occurrence of CTCs in pa-
tient's blood detected by a reliable, inexpensive and 
relatively fast method for CTCs enrichment and 
evaluation based on cytomorphological analysis by 
means of vital fluorescence staining.
References
1. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis 
shows that detection of circulating tumor cells indicates poor 
prognosis in patients with colorectal cancer. Gastroenterolo-
gy. 2010; 138(5): 1714–1726, doi: 10.1053/j.gastro.2010.01.008, 
indexed in Pubmed: 20100481.
2. Liberko M, Kolostova K, Bobek V. Essentials of circulating 
tumor cells for clinical research and practice. Crit Rev On-
col Hematol. 2013; 88(2): 338–356, doi: 10.1016/j.critrev-
onc.2013.05.002, indexed in Pubmed: 23830807.
Figure 1. Morphology of CTCs isolated from patients with CRC. A. CTCs captured on the separation membrane; B. CTCs 
after successful short term in vitro cultivation — 5 days after isolation. Cells were visualized by vital fluorescent staining with 
NucBlue® and Celltracker® as described in Material and methods. Bars represent 10 μm.
A B
5Circulating tumor cells and colorectal cancer staging
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0005
www.fhc.viamedica.pl
3. Eliasova P, Kolostova K, Kobierzycki C, et al. Clinical stud-
ies monitoring circulating and disseminated tumor cells in 
gastrointestinal cancers. Folia Histochem Cytobiol. 2013; 
51(4): 265–277, doi: 10.5603/FHC.2013.0037, indexed in 
Pubmed: 24497131.
4. Huang MY, Tsai HL, Huang JJ, et al. Clinical Implications 
and Future Perspectives of Circulating Tumor Cells and Bio-
markers in Clinical Outcomes of Colorectal Cancer. Transl 
Oncol. 2016; 9(4): 340–347, doi: 10.1016/j.tranon.2016.06.006, 
indexed in Pubmed: 27567958.
5. Tan C, Zhou L, El-Deiry W. Circulating tumor cells ver-
sus circulating tumor DNA in colorectal cancer: pros and 
cons. Curr Colorectal Cancer Rep.  2016; 12(3): 151–161, 
doi: 10.1007/s11888-016-0320-y, indexed in Pubmed: 
27516729.
6. Kolostova K, Matkowski R, Jędryka M, et al. The added val-
ue of circulating tumor cells examination in ovarian cancer 
staging. Am J Cancer Res. 2015; 5(11): 3363–3375, indexed 
in Pubmed: 26807317.
7. Kolostova K, Spicka J, Matkowski R, et al. Isolation, 
primary culture, morphological and molecular charac-
terization of circulating tumor cells in gynecological can-
cers. Am J Transl Res. 2015; 7(7): 1203–1213, indexed in 
Pubmed: 26328005.
8. Cegan M, Kolostova K, Matkowski R, et al. In vitro cul-
turing of viable circulating tumor cells of urinary blad-
der cancer. Int J Clin Exp Pathol. 2014; 7(10): 7164–7171, 
indexed in Pubmed: 25400813.
9. Bobek V, Matkowski R, Gürlich R, et al. Cultivation of cir-
culating tumor cells in esophageal cancer. Folia Histochem 
Cytobiol. 2014; 52(3): 171–177, doi: 10.5603/FHC.2014.0020, 
indexed in Pubmed: 25308732.
10. Kolostova K, Zhang Y, Hoffman RM, et al. In vitro culture 
and characterization of human lung cancer circulating tumor 
cells isolated by size exclusion from an orthotopic nude-mouse 
model expressing red fluorescent protein. J Fluoresc. 2014; 
24(5): 1531–1536, doi: 10.1007/s10895-014-1439-3, indexed 
in Pub med: 25141982.
11. Hermanek P. pTNM and residual tumor classifications: prob-
lems of assessment and prognostic significance. World J Surg. 
1995; 19(2): 184–190, indexed in Pubmed: 7754621.
12. Cohen SJ, Punt CJA, Iannotti N, et al. Relationship 
of circulating tumor cells to tumor response, progres-
sion-free survival, and overall survival in patients with 
meta static colorectal cancer. J Clin Oncol. 2008; 26(19): 
3213–3221, doi: 10.1200/JCO.2007.15.8923, indexed in Pub-
med: 18591556.
13. Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance 
of circulating tumor cells in patients with metastatic colorectal 
cancer. Ann Oncol. 2009; 20(7): 1223–1229, doi: 10.1093/ann-
onc/mdn786, indexed in Pubmed: 19282466.
14. Groot Koerkamp B, Rahbari NN, Büchler MW, et al. Cir-
culating tumor cells and prognosis of patients with resect-
able colorectal liver metastases or widespread metastatic 
colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013; 
20(7): 2156–2165, doi: 10.1245/s10434-013-2907-8, indexed 
in Pubmed: 23456317.
15. Matsusaka S, Suenaga M, Mishima Y, et al. Circulating tu-
mor cells as a surrogate marker for determining response to 
chemotherapy in Japanese patients with metastatic colorectal 
cancer. Cancer Sci. 2011; 102(6): 1188–1192, doi: 10.1111/j.
1349-7006.2011.01926.x, indexed in Pubmed: 21401804.
16. Schuster R, Max N, Mann B, et al. Quantitative real-time 
RT-PCR for detection of disseminated tumor cells in pe-
ripheral blood of patients with colorectal cancer using dif-
ferent mRNA markers. Int J Cancer. 2004; 108(2): 219–227, 
doi: 10.1002/ijc.11547, indexed in Pubmed: 14639606.
17. Sher YP, Shih JY, Yang PC, et al. Prognosis of non-small 
cell lung cancer patients by detecting circulating can-
cer cells in the peripheral blood with multiple marker 
genes. Clin Cancer Res. 2005; 11(1): 173–179, indexed in 
Pubmed: 15671543.
18. Oberg ANV, Lindmark GE, Israelsson ACE, et al. Detec-
tion of occult tumour cells in lymph nodes of colorectal can-
cer patients using real-time quantitative RT-PCR for CEA 
and CK20 mRNAS. Int J Cancer. 2004; 111(1): 101–110, 
doi: 10.1002/ijc.20231, indexed in Pubmed: 15185350.
19. Ghajar CM, Bissell MJ. Metastasis: Pathways of parallel 
progression. Nature. 2016; 540: 528–529, doi: 10.1038/na-
ture21104, indexed in Pubmed: 27974802.
20. Hosseini H, Obradović MMS, Hoffmann M, et al. Early 
dissemination seeds metastasis in breast cancer. Nature. 
2016; 540: 552–558, doi: 10.1038/nature20785, indexed in 
Pubmed: 27974799.
21. Yen LC, Yeh YS, Chen CW, et al. Detection of KRAS on-
cogene in peripheral blood as a predictor of the response 
to cetuximab plus chemotherapy in patients with metastatic 
colorectal cancer. Clin Cancer Res. 2009; 15(13): 4508–4513, 
doi: 10.1158/1078-0432.CCR-08-3179, indexed in Pub-
med: 19549774.
Submitted: 20 October, 2016 
Accepted after reviews: 19 April, 2017 
Available as AoP: 28 April, 2017
